{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT02677324","nct_id":"NCT02677324","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02677324. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles","label":"ABT199","type":"EXPERIMENTAL"}],"collaborators":["AbbVie"],"completion_date":{"date":"2022-02-07","type":"ACTUAL"},"conditions":["Waldenstrom Macroglobulinemia"],"enrollment":{"count":33,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"ABT199","otherNames":["Venetoclax"],"type":"DRUG"}],"last_update":"2022-05-11","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2020-02-14","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Response Rate","timeFrame":"2 years"}],"references":[{"citation":"Castillo JJ, Guijosa A, Allan JN, Siddiqi T, Advani RH, Flynn CA, Meid K, Budano N, Nguyen J, Ramirez-Gamero A, Tsakmaklis N, Hunter ZR, Patterson CJ, Treon SP, Sarosiek S. Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenstrom macroglobulinemia. Blood Adv. 2025 Oct 14;9(19):4842-4847. doi: 10.1182/bloodadvances.2025016890.","pmid":"40674749","type":"DERIVED"},{"citation":"Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, White TP, Flynn CA, Sarosiek S, Branagan AR, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Patterson CJ, Hunter ZR, Davids MS, Furman RR, Treon SP. Venetoclax in Previously Treated Waldenstrom Macroglobulinemia. J Clin Oncol. 2022 Jan 1;40(1):63-71. doi: 10.1200/JCO.21.01194. Epub 2021 Nov 18.","pmid":"34793256","type":"DERIVED"}],"start_date":{"date":"2016-05-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia","url":"https://clinicaltrials.gov/study/NCT02677324"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02677324"}